Video

Dr. Hoos Describes Ipilimumab and Future Immunotherapies

Author(s):

Axel Hoos, MD, PhD

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses ipilimumab (Yervoy) and how it is a first-in-class agent that enhances activation of T cells. He elaborates that Bristol-Myers Squibb plans to build upon this success with their new drug the anti-PD-1 agent MDX-1106.

Related Videos
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

FDA
May 29th 2024

FDA Grants Accelerated Approval to Selpercatinib for Pediatric RET+ Metastatic Thyroid Cancer or Solid Tumors

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Michiel Van der Heijden, MD, PhD, medical oncologist and research group leader at Netherlands Cancer Institute
May 29th 2024

Frontline Nivolumab/Chemo Approved in Europe for Unresectable or Metastatic Urothelial Cancer

Sarah ES Leary, MD, MS, of Fred Hutchinson
May 28th 2024

Tovorafenib Offers an Efficacious Option for R/R BRAF-Positive Pediatric Low-Grade Glioma